Chronic lymphocytic leukaemia+1
Not recruitingStudy on the Safety and Effectiveness of BCN-CP01 for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study on the Safety and Effectiveness of BCN-CP01 for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Disease:Chronic lymphocytic leukaemiaB-cell small lymphocytic lymphoma
- Substances:–
Spain- Participants:18–64 years · 65+ years
- Sponsor:Lakefront Biotherapeutics












